Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Pfizer Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Pfizer

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CALAN SR verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 019152-001 Dec 16, 1986 AB RX Yes Yes   See Pricing   See Pricing
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006 DISCN No No 6,257,233   See Pricing   See Pricing
Pfizer ADVIL COLD AND SINUS ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 019771-001 Sep 19, 1989 OTC Yes Yes   See Pricing   See Pricing
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 AB RX Yes No 6,150,366   See Pricing Y   See Pricing
Pfizer HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 201370-003 Jul 21, 2011 RX Yes Yes   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-003 Jan 30, 2004 4,572,909*PED   See Pricing
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-001 Apr 26, 1994 5,591,454   See Pricing
Pfizer Pharms ACCURETIC hydrochlorothiazide; quinapril hydrochloride TABLET;ORAL 020125-003 Dec 28, 1999 4,743,450*PED   See Pricing
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-006 Jan 30, 2004 5,686,104*PED   See Pricing
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997 5,457,109   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2004-11-19
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 2010-03-29
➤ Subscribe Capsules 200 mg/38 mg ➤ Subscribe 2016-02-16
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2009-04-07
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07
➤ Subscribe Tablets 100 mg ➤ Subscribe 2004-10-25
➤ Subscribe Capsules 200 mg/30 mg ➤ Subscribe 2004-12-27
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 150 mg and 200 mg ➤ Subscribe 2005-11-09
➤ Subscribe Tablets 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg ➤ Subscribe 2006-12-29
➤ Subscribe Tablets 2.5 mg/40 mg ➤ Subscribe 2009-09-17
Premature patent expirations for PFIZER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  See Pricing   See Pricing

Supplementary Protection Certificates for Pfizer Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2107069 35/2013 Austria   See Pricing PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC AND INSULIN ASPART UND BELIEBIGE ZN2+-KOMPLEXE DAVON; REGISTRATION NO/DATE: EU/1/12/806/001, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008 (MITTEILUNG) 20180123
0473687 99C0008 Belgium   See Pricing PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
2107069 C300597 Netherlands   See Pricing PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
1746976 1790033-3 Sweden   See Pricing PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.